Table 2.
Level of evidence-based of most frequently used medicines in each indication
| Medicine | Indication | Number (%) | Level of evidence | Ongoing clinical trial |
|---|---|---|---|---|
| Rituximab | Complications of organ or tissue transplant, failure or rejection | 7 (3.0) | 4 | Phase III |
| Pemphigus | 6 (2.6) | 4 | Phase III | |
| Myasthenia gravis | 4 (1.7) | 4 | Phase II | |
| Systemic lupus erythematosus (SLE) | 4 (1.7) | 2b | – | |
| Cryoglobulinemic purpura | 3 (1.3) | 2b | Phase II | |
| Lupus nephritis | 3 (1.3) | 2b | – | |
| Wegener granulomatosis | 3 (1.3) | 1b | Phase III | |
| Encephalitis, myelitis and encephalomyelitis | 2 (0.8) | 4 | – | |
| Glomerulonephritis, membranous | 2 (0.8) | 4 | Phase III | |
| Idiopathic thrombocytopenic purpura | 2 (0.8) | 1b | Phase III | |
| Relapsing polychondritis | 2 (0.8) | 4 | – | |
| Glomerulonephritis, minimal change disease | 1 (0.4) | 2b | Phase III | |
| Graft-versus-host disease | 1 (0.4) | 2a | Phase II | |
| Lymphoproliferative disorder | 1 (0.4) | 2b | – | |
| Neuromyelitis optica | 1 (0.4) | 4 | Phase I | |
| Polymyositis | 1 (0.4) | 4 | – | |
| Polyradiculoneuropathy, chronic inflammatory demyelinating | 1 (0.4) | 4 | – | |
| Sarcoidosis | 1 (0.4) | 4 | Phase II | |
| Sjögren syndrome | 1 (0.4) | 2b | Phase II | |
| Systemic scleroderma | 1 (0.4) | 2b | Phase II | |
| Thrombocytopenia in SLE | 1 (0.4) | 4 | – | |
| Waldenström macroglobulinaemia | 1 (0.4) | 2b | Phase II | |
| Subtotal | 49 (21.1) | |||
| Botulinum toxin | Anal fissure | 13 (5.6) | 1a | Phase IV |
| Esophageal achalasia | 8 (3.4) | 1a | – | |
| Generalized hyperhidrosis | 2 (0.8) | 1a | Phase IV | |
| Eyelid retraction | 1 (0.4) | 2b | Phase IV | |
| Myofascial pain | 1 (0.4) | 2b | Phase IV | |
| Subtotal | 25 (10.8) | |||
| Omalizumab | Chronic urticaria | 7 (3.0) | 2b | Phase III |
| Food-induced anaphylaxis | 3 (1.3) | 4 | Phase II | |
| Cold-induced urticaria | 2 (0.8) | 4 | – | |
| Extrinsic allergic asthma | 1 (0.4) | 4 | Phase IV | |
| Nasal polyps | 1 (0.4) | 4 | Phase IV | |
| Subtotal | 14 (6.0) |
Information about the other used medicines is available in annex 2 of the supplementary material